The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction
Open accessAbstract
Many malignant human tumors, including melanomas, are auxotrophic for arginine due to reduced expression of argininosuccinate synthetase-1 (ASS1), the rate-limiting enzyme for arginine biosynthesis. Pegylated arginine deiminase (ADI-PEG20), which degrades extracellular arginine, resulting in arginine deprivation, has shown favorable results in clinical trials for treating arginine-auxotrophic tumors. Drug resistance is the major obstacle for effective ADI-PEG20 usage. To elucidate mechanisms of resistance, we established several ADI-PEG20–resistant (ADIR) variants from A2058 and SK-Mel-2 melanoma cells. Compared with the parental lines, these ADIR variants showed the following characteristics: (i) all ADIR cell lines showed elevated ASS1 expression, resulting from the constitutive binding of the transcription factor c-Myc on the ASS1 promoter, suggesting that elevated ASS1 is the major mechanism of resistance; (ii) the ADIR cell lines exhibited enhanced AKT signaling and were preferentially sensitive to PI3K/AKT inhibitors, but reduced mTOR signaling, and were preferentially resistant to mTOR inhibitor; (iii) these variants showed enhanced expression of glucose transporter-1 and lactate dehydrogenase-A, reduced expression of pyruvate dehydrogenase, and elevated sensitivity to the glycolytic inhibitors 2-deoxy-glucose and 3-bromopyruvate, consistent with the enhanced glycolytic pathway (the Warburg effect); (iv) the resistant cells showed higher glutamine dehydrogenase and glutaminase expression and were preferentially vulnerable to glutamine inhibitors. We showed that c-Myc, not elevated ASS1 expression, is involved in upregulation of many of these enzymes because knockdown of c-Myc reduced their expression, whereas overexpressed ASS1 by transfection reduced their expression. This study identified multiple targets for overcoming ADI-PEG resistance in cancer chemotherapy using recombinant arginine-degrading enzymes. Mol Cancer Ther; 12(11); 2581–90. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the use of arginine-catabolizing enzymes may not be an effective therapeutic strategy for all ASS1-deficient cancers, as some ADI-treated tumors have been found to re-express ASS1 (Feun et al., 2012; Long et al., 2013; Shen et al., 2003).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Long et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
The mechanism of eukaryotic translation initiation and principles of its regulation
Jackson, R. J., Hellen, C. U. T., & Pestova, T. V. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2838 · Cited by 2,759
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Molecular imaging of cancer with positron emission tomography
Gambhir, S. S. (2002) · Nature reviews. Cancer · doi:10.1038/nrc882 · Cited by 1,658
Coping with stress: eIF2 kinases and translational control
Wek, R. C., Jiang, H.-Y., & Anthony, T. G. (2005) · Biochemical Society Transactions · doi:10.1042/bst0340007 · Cited by 1,353
Dang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188
Genomic targets of the human c-Myc proteinPreprint
Fernandez, P. C., Frank, S. R., Wang, L., Schroeder, M., Liu, S., Greene, J. R., Cocito, A., & Amati, B. B. (2003) · Genes & Development · doi:10.1101/gad.1067003 · Cited by 963
Cited by
Sorted by citations
Items 101–121 of 121
BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
Panda, P. K., Mafra, A. C. P., Bastos, A. C. S., Cao, L., Bonet, M. S., Brashears, C. B., Chen, E. Y., Benedict-Hamilton, H. M., Ehrhardt, W. R., Bomalaski, J. S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2548 · Cited by 4
The mTOR Complexes in Cancer Cell Metabolism
Lynch, T. P., Moloughney, J. G., & Jacinto, E. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_2 · Cited by 3
Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19α protein
Lee, H., Park, G., Kim, S., Son, B., Joo, J., Park, H. H., & Park, T. H. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12218-0 · Cited by 3
Hanssen, K. M., Murray, J. E., Pandher, R., Alfred, S., Gamble, L. D., Brand, J., Mosmann, E., Kusuma, F. K., Mak, C., Kearns, A., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03502-8 · Cited by 2
Tumor starvation by L-arginine deprivation
Fried, R., Carlton, R. M., & Fried, D. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824013-7.00005-5 · Cited by 2
Wilczak, M., Surman, M., Jankowska, U., Skupień-Rabian, B., & Przybyło, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151749 · Cited by 2
Targeting Cancer Metabolism Dependencies
Harding, K. (2023) · CABI eBooks · doi:10.1079/9781789245820.0004 · Cited by 2
Conceptualizing Digital Addiction as Glutamine Inhibition and Glutamate Acceleration (GIGA)
Bishop, J. (2019) · Advances in psychology, mental health, and behavioral studies (APMHBS) book series · doi:10.4018/978-1-5225-8449-0.ch004 · Cited by 2
Energetics of whole genome doubling and genomic instability
Beck, R. J., Tagal, V., Amin, S. B., Bakhoum, S. F., Maley, C. C., Verhaak, R. G. W., Gomes, A. P., & Andor, N. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217878 · Cited by 3
Li, J., Zheng, Y., Chen, C., Lin, Z., Pan, J., Jiang, F., & Zhong, W. (2025) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2025.111912 · Cited by 1
Mechanisms of l-Arginine-Auxotrophic Response and Their Cancer Therapeutic Implications
Tsai, W.-B., Long, Y., Savaraj, N., Feun, L. G., & Kuo, M. T. (2016) · Springer eBooks · doi:10.1007/978-3-319-26009-9_44 · Cited by 1
Self-citationThe Fate of Glutamine in Human Metabolism. The interplay with glucose in proliferating cellsPreprint
Mazat, J., & Ransac, S. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/477224 · Cited by 1
Fennell, D. A. (2021) · Respiratory disease series · doi:10.1007/978-981-15-9158-7_24
Negahdaripour, M., Zarei, M., Sabetian, S., & Rahbar, M. R. (2022) · Current Proteomics · doi:10.2174/1570164619666220513123509
Additional file 1 of Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Li, J.-M., Chang, W.-H., Li, L., Yang, D. C. H., Hsu, S.-W., Kenyon, N. J., & Chen, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26589909
Zhang, Z., Lin, Z., Li, W., Chen, B., Liu, Y., Gao, H., & Xu, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0338802
Li, M., Huang, X.-Y., Liu, X.-H., Shao, H., Hu, X.-Y., Su, M., Ni, S., Cao, H.-H., Tian, G., Zhu, X.-Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03466
Mou, H., Yakovishina, V., Chen, Y., Xiao, M., Dunne, M., Shi, N., Thomas, M., DeRosa, K. M., Li, H., Liu, Q., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.27.707779
Chessel, E., Khatir, W., Silva, A. C. B. S., Abbe, P., Béranger, G. E., Ding, Z., Passeron, T., Ben‐Sahra, I., Montaudié, H., Robert, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.17.712479
Therapeutic potential of anticancer enzymes derived from halophilic microorganisms
Faruqui, R., Kureshi, M., Bhuptani, M., Tarasadiya, V., Patel, A., & Upadhye, V. (2026) · Discover Applied Sciences · doi:10.1007/s42452-026-08685-z
Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges
Freitas-Dias, C., & Mendes, C. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_14
Metadata
- Authors
- Long, Y., Tsai, W.-B., Wangpaichitr, M., Tsukamoto, T., Savaraj, N., Feun, L. G., & Kuo, M. T.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Kuo, Macus Tien
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-11-01
- Volume
- 12
- Issue
- 11
- Pages
- 2581-2590
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- PMC
- PMC3839414
- OpenAlex
- W2108745454
- Cited by
- 121
- References
- 48
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 5 · 2023: 6 · 2022: 11 · 2021: 20 · 2020: 6 · 2019: 11 · 2018: 10 · 2017: 8 · 2016: 12 · 2015: 11 · 2014: 3 · 2013: 1
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK2 BX001289)
- National Cancer Institute (R01CA149260, R0I-CA149260)
- National Institute of Neurological Disorders and Stroke (R21NS074151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- ADI-PEG20, melanoma, arginine auxotrophy, argininosuccinate synthetase 1, c-Myc, Akt signaling, mTOR signaling, Warburg effect, glycolysis, glutamine addiction, glutaminase, drug resistance mechanisms
- MeSH terms
- Arginine, Argininosuccinate Synthase, Glucose, Glutamine, Humans, Hydrolases, Lipids, Melanoma, Polyethylene Glycols, Transfection, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-myc, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
